Roche Holding AG’s lung cancer drug scored a big win against a standard therapy in a study this week. Now, the Swiss drugmaker is turning to artificial intelligence to find patients who can benefit.
This content was published on
2 minutes
Bloomberg
When given after surgery to remove lung tumours, Roche’s Alecensa cut the risk of either cancer recurrence or death by 76% compared with standard chemotherapy, according to results from a primary analysis of the trial released Wednesday. The drug could “potentially alter the course of this disease,” Roche Chief Medical Officer Levi Garraway said in a statement.
But finding patients to treat may be difficult: the study examined the effects on people with an error in a gene called ALK that’s found in only about 4% to 5% of lung cancer patients. Most of them are younger and less likely to have smoked than typical lung tumour patients, and often go undiagnosed early on.
To solve the problem, Roche will use an AI collaboration with Israeli tech company Medial EarlySign Ltd. to help doctors determine when to use CT scans. While the technology, called LungFlag, doesn’t currently detect ALK-positive patients, the company said on Saturday that it’s actively exploring how to expand it so they can benefit.
That will help find tumours before they spread and while needed surgery is still possible, said Charlie Fuchs, Roche’s head of oncology and haematology drug development.
“Sometimes when you really use deep data algorithms, you may find things that identify people who are non-smokers and yet at risk,” Fuchs said in an interview. “We hope more patients can be found early and benefit from this.”
Roche has said it will file the Alecensa study results with regulators for approval. The full results were presented Saturday at the European Society for Medical Oncology meeting in Madrid. Alecensa is already approved in the US, Europe, Japan and China for patients with ALK-positive metastatic lung cancer.
Analysts anticipate that Alecensa will generate CHF1.56 billion ($1.75 billion) in sales this year. That it would be a blockbuster medicine even though it treats such a small portion of lung cancer patients shows that effective drugs don’t have to serve a big patient population to be scientific and financial successes, Fuchs said.
Living longer: What do you think about the longevity trend?
The longevity market is booming thanks in part to advances in the science of ageing. What do you think of the idea of significantly extending human lifespan?
Swiss president visits region affected by glacier collapse
This content was published on
Swiss President Karin Keller-Sutter spoke with communities affected by the Birch glacier collapse, which buried the village of Blatten.
This content was published on
On Saturday the Lake Geneva, Valais and Basel regions are expected to record the first tropical day of the year, with temperatures exceeding 30°C.
This content was published on
The Swiss economy saw the clouds that had gathered over its prospects lift somewhat in May. However, the KOF economic barometer is still below its long-term average.
Direct operations too dangerous in Swiss landslide valley
This content was published on
By Friday morning 365 people had been forced to leave their homes because of Wednesday's landslide in the Swiss village of Blatten.
Franco-Swiss raclette war set to be settled on Sunday
This content was published on
The battle for the world's largest raclette will be transformed on Sunday in Saint-Gingolph, canton Valais, into a raclette of friendship served at the border.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.